Research programme: antibacterials - Millennium/Wyeth

Drug Profile

Research programme: antibacterials - Millennium/Wyeth

Alternative Names: Antibacterials research programme - Millennium/Wyeth

Latest Information Update: 22 Mar 2002

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals; Wyeth
  • Developer Millennium Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 22 Mar 2002 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 15 Jan 2001 Millennium and Wyeth-Ayerst identify preclinical antibacterial compound
  • 11 Jan 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top